Transactions – BroadOak Capital Partners

Advisory Transactions

Relationship Based. Authentic Partnership. Common Goals.

6/2022

Sale of the company to Medix Biochemica

5/2022

Sale of the company to Biosynth Carbosynth

2/2022

Aquisition of antibodies-online

2/2022

Acquisition of FlowMetric

1/2022

Sale of the company to Maravai LifeSciences

12/2021

Sale of the company to Element Materials Technology

11/2021

Sale of the company to Cytek Biosciences

10/2021

Sale of the company to Element Materials Technology

4/2021

Sale of the company to Vitruvian

7/2019

Sale of the company to Versiti

4/2019

Sale of the company to BioLife Solutions

10/2018

Sale of the company to PerkinElmer

9/2018

Sale of company to Thompson Street Capital Partners

2/2018

Sale of the company to LGC Limited

7/2017

Sale of the company to Thermo Fisher Scientific Inc.

6/2017

Sale of the company to Unchained Labs

6/2017

Exclusive placement agent for Labconnect, Inc.

1/2017

Sale of the company to Takara Bio Inc.

11/2016

Sale of the company to Thermo Fisher Scientific Inc.

10/2016

Strategic acquisition of TriLink Biotechnologies

10/2016

Strategic acquisition of Cygnus

7/2016

Sale of the company to PerkinElmer

7/2016

Clarity Medical Systems has sold its RetCam Ophthalmic Imaging System business to Natus Medical

3/2016

Sale of the company to Lab Corporation of America

3/2016

Strategic equity investment in Vector Laboratories

7/2015

Sale of the company to OpGen, Inc.

9/2014

Sale of the iPS Cell Business Unit of Stemgent ReproCELL, Inc.

8/2014

Sale of miRInform Thyroid and Pancrease Test to PDI Inc. (now Interpace Diagnostics)

7/2014

Sale of company to StoneCalibre

3/2014

Equity investment and strategic collaboration with Brooks Automation, Inc.

2/2014

Sale of in-vivo preclinical services business to BIOQUAL, Inc.

8/2013

Sale of sequencing services business to BioReference Laboratories, Inc.

7/2013

Sale of the Life Science business of SDIX to OriGene Technologies, Inc.

4/2013

Sale of UVP LLC to Analytik Jena AG

12/2012

Sale of BioServices business to Precision Bioservices

10/2012

Sale of Food Safety and GMO businesses
to Romer Labs

9/2012

Sale of preclinical in-vivo imaging business to Bruker

3/2012

Exclusive placement agent for OpGen, Inc.

12/2011

BroadOak Partners provided financial advisory
services to Quanta Biosciences

9/2011

Non-exclusive license agreement with QIAGEN

9/2011

BroadOak retained to provide ongoing financial
advisory services

9/2010

SVT gains exclusive rights in China to ENMD-2076 through investment in EntreMed, Inc.

7/2010

Replacement and expansion of Cayman Chemical Company’s debt facilities

6/2010

Acquisition of Hyaluron, Inc.

4/2010

Acquisition of GlobalStem, Inc.

12/2009

Sale of in-vivo preclinical CRO services business to
Taconic Farms, Inc.

10/2009

Sale of Alpha Innotech Corp. to Cell Biosciences, Inc.

10/2009

Collaboration and license agreement with Novartis

8/2009

Sale of non-core assets to Intrexon Corporation

3/2009

Sale of Assay Designs, Inc. to Enzo Biochem, Inc.

10/2008

Sale of Semrock Inc. to IDEX Corp

4/2008

Acquisition of biodefense vaccines business from
Avecia Biologics Limited

6/2007

Sale of Fluorescent Detection Products Business

7/2006

Sale of In Vitro Technologies, Inc to Celsis International Plc

3/2006

Acquisition of sales and marketing rights to EpiPen in Canada from Allerex Laboratory

12/2005

Acquisition of Control Delivery Systems

10/2005

Sale of NovaScreen Biosciences to Caliper Life Sciences

10/2005

Merger with xantra

7/2001

Sale of Sybron Biochemical Division to Novozymes

Code for Load More button – Do Not Delete

Partner with BroadOak

Investing

Advisory

About

Portfolio

Transactions

News

Contact

Team

Investor Login

Join our newsletter.

Sign up to stay informed about our work.

2022 © BroadOak Capital Partners, LLC.
All rights reserved.

Member FINRA | SIPC
Business Continuity Disclosure
Privacy Policy